Comparison of treatment costs in inadequately controlled type 2 diabetes in Germany based on the APOLLO trial with insulin glargine

Journal of Medical Economics

Volumn 12, Issue 2, 2009, Pages 87-97

  Bretzel, Reinhard G ^a   Dippel, Franz Werner ^b   Linn, Thomas ^a   Neilson, Aileen Rae ^c  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^c HealthEcon Ltd   (Switzerland)

Author keywords

APOLLO trial; Cost analysis; Insulin glargine; Insulin lispro; Type 2 diabetes

Indexed keywords

GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; INSULIN LISPRO; METFORMIN; ORAL ANTIDIABETIC AGENT;

ARTICLE; CLINICAL TRIAL; COST CONTROL; DEVICE; DISPOSABLE EQUIPMENT; DRUG COST; DRUG DOSE COMPARISON; GERMANY; GLUCOSE TOLERANCE TEST; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; INTERMETHOD COMPARISON; NEEDLE; NON INSULIN DEPENDENT DIABETES MELLITUS; SENSITIVITY ANALYSIS; ERRATUM; ERROR;

COSTS AND COST ANALYSIS; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; EQUIPMENT AND SUPPLIES, HOSPITAL; GERMANY; HEALTH CARE COSTS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SENSITIVITY AND SPECIFICITY;

EID: 67949100214     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696990902949614     Document Type: Article

References (25)

1. Holman RR, Paul SK, Bethel MA, et al. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589.
2. Amiel SA, Dixon T, Mann R, et al. Hypoglycaemia in type 2 diabetes: Review Article. Diabet Med 2008;25:245-254.
3. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32(1):193-203.
4. Matthaei S, Häring HU. Behandlung des Diabetes mellitus Typ 2. Diabetologie 2008;3(Suppl 2):S157-S161.
5. Bretzel RG, Nuber U, Landgraf W, et al. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 2008;371:1073-1084.
6. Drummond M, Barbieri M, Cook J, et al. Transferability of economic evaluations across jurisdictions. Value Health. 2009; forthcoming.
7. Rote Liste®Service GmbH, Arzneimittelverzeichnis für Deutschland (einschließlich- EU-Zulassungen und bestimmter Medizinprodukte), Frankfurt/Main, 2008;. Available at: www.rote-liste.de
8. Oliveira JH, Kazda C, Simpson A, et al. Basal insulin glargine vs. insulin lispro in type 2 diabetes. Correspondence. Lancet 2008;372:371-372.
9. Janka HU, Högy B. Economic evaluation of the treatment of type 2 diabetes with insulin glargine based on the LAPTOP trial. Eur J Health Econ 2008;9:165-170.
10. Roper Western Europe Diabetes Patient Survey 2004; from GfK Healthcare. Available at: www.diabetes-world.net/Portalf% C3%BCr-Patienten-und- Interessierte/Diabetes-behandeln/ Insulininjektion/Pennadeln - Viele-sparen-am-falschen-Ende. htm?ID=3367.
11. Pinget, M: Pressekonferenz "Vom richtigen Umgang mit dem Insulinpen - Weil es unter die Haut geht ", 28.03.2006;. Available at: http://diabetesprofi.diabetes-kids.de/index2.php?option=com-content&do-pdf= 1&id=46
12. Ypsomed GmbH, Otto-Volger Strasse 7c, 65843 Sulzbach/Taunus. Available at: www.ypsomed.de
13. Florian Müller GmBh - the friendly mail-order for diabetics, Wichmannstrasse 4, 22607 Hamburg. Available at: www.florian-mueller.de
14. Leese GP, Wang J, Broomhall J, et al. Frequency of severe hypoglycaemia requiring emergency treatment in type 1 and type 2 diabetes. Diabet Med 2003;26:1176-1180.
15. Allicar MP, Megas F, Houzard S, et al. Frequency and costs of hospital stays for hypoglycaemia in France in 1995. Presse Med 2000;29:657-661.
16. Holstein A, Plaschke A, Egberts EH. Incidence and costs of severe hypoglycaemia. Diabetes Care 2002;25:2109-2110.
17. Linn T, Landgraf W, Bretzel RG. Basal insulin glargine vs. prandial lispro in type 2 diabetes - Authors' reply. Correspondence. Lancet 2008;372:372.
18. Heinemann L. Control group does not reflect treatment reality in Germany. Lancet 2008;371(9618):1047-1048.
19. Schwabe U, Paffrath D. Arzneiverordnungs - Report 2007, Aktuelle Daten, Kosten Trends und Kommentare. Heidelberg: Springer Medizin Verlag, 2008.
20. Matthaei S, Bierwirth R, Fritsche A, et al. Medikamentöse antihyperglykämische Therapie des Diabetes mellitus Typ 2. Update der Evidenzbasierten Leitlinie der DDG, 13.10.2008;. Available at: http://www.deutsche-diabetes-gesellschaft.de/
21. Bretzel RG, Eckhard M, Landgraf W, Linn T. Initiating insulin therapy in type 2 diabetic patients failing improvement with oral hypoglycemic agents: Basal or prandial insulin? The APOLLO trial. Diabetes Care 2009 (in press).
22. Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357(17):1716-1730. (Pubitemid 350005153)
23. Arnolds S, Rave K. Basal insulin glargine vs. prandial insulin in type 2 diabetes. Correspondence. Lancet 2008;372:370-371
24. Frick M, Knollmeyer J, Riederer H, et al. Modern insulins - comments on facts and assumptions in a recent Editorial. Letter. Diabetologia 2008;51:689-691.
25. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Diabetologia 2008;51(1):8-11.